Rewind raises €15.2M series A

Catholic University Leuven (KU Leuven) spinout Rewind Therapeutics (Leuven, Belgium) raised €15.2 million ($18.1 million) on Jan. 4 in a series A round led by Boehringer Ingelheim Venture Fund, Merck Ventures and Participatiemaatschappij Vlaanderen. KU Leuven's Center for Drug Design and Discovery (CD3) and KU Leuven Gemma Frisius Fonds also participated.

Rewind is developing remyelination small molecule therapies for multiple sclerosis and other myelin-related disorders. It will use the series A funds to advance its first candidate into the clinic...